Abstract: Antibody-saccharide-complexes and methods and uses related to analysis of cells. Also disclosed is a method of selection of new antibody with CHO-specificity and to a use of antibodies produced for the analysis of stem cells or cancer cells or other cells or tissues known to bind to CHO-antibodies.

Abstract: A complex of Tra-antibody bound to an isolated glycan comprising type I—N-acetyllactosamine comprising target structure, and methods and uses utilizing said complex.

Abstract: The invention describes novel reagents that can be applied for analysis of the quality of human cells. The method evaluates the integrity of the plasma membrane of the cells by detecting novel glyco structures found only intracellularly. The method can be applied, for example, to demonstrate exposure of therapeutic cell preparation to potentially harmful conditions. It can also be used as a quality control tool in methods in which intact cell membrane is essential and it can be applied in separation of damaged cells from non- damaged.

Abstract: The invention is directed to the analysis of novel acidic glycan markers of several types of human cells. The analysis is performed by mass spectrometry or specific binder molecules.

Abstract: This invention relates to antibody engineering technology. More particularly, the present invention relates to human IgM antibodies and derivatives thereof, which have novel binding specificity with regard to several oligosaccharide sequences and/or xenoantigenic sialic acid residue. The present invention also relates to processes for making and engineering such novel saccharide and/or NeuGc-binding monoclonal antibodies and to methods for using these antibodies and derivatives thereof in the field of immunodiagnostics, enabling qualitative and quantitative determination of xenoantigenic NeuGc in biological and raw material samples, as well as in immunotherapy, enabling blocking of xenoantigenic NeuGc in patients.

Abstract: The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies.

Abstract: The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies.

Abstract: The invention describes novel compositions of glycans, glycomes, from human embryonic stem cells, and especially novel subcompositions of the glycomes with specific monosaccharide compositions and glycan structures. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore, the invention is directed to stem cells carrying the modified glycomes on their surfaces. The glycomes are preferably analysed by profiling methods able to detect reproducibly and quantitatively numerous individual glycan structures at the same time. The most preferred type of the profile is a mass spectrometric profile. The invention specifically revealed novel target structures and is especially directed to the development of reagents recognizing the structures.